THE US Food and Drug
Administration (FDA) has slapped
a boxed warning on the labelling
requirements for fluoroquinolone
antibacterial drugs for systemic
use on the basis that the drug
is associated with disabling and
potentially permanent side effects
of the tendons, muscles, joints,
nerves, and central nervous system
that can occur together in the same
patient.
As a result, clinicians will only be
able to prescribe fluoroquinolones
for use in patients who have no
other treatment options for acute
bacterial sinusitis, acute bacterial
exacerbation of chronic bronchitis
and uncomplicated urinary tract
infections because the risk of
these serious side effects generally
outweighs the benefits in these
patients.
For details see www.fda.gov.The above article was sent to subscribers in Pharmacy Daily's issue from 27 Jul 16 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 27 Jul 16
AUSTRALIA needs more pharmacists than ever, in the face of an ageing population and rising healthcare demands, according to the Pharmaceutical Society of Australia (PSA).
INTERN pharmacists from Monash University are set to join Victoria’s immunisation workforce under a new Secretary Approval by the Victorian Health Department.
VIRTUAL care delivered through telephone or video conference has now embedded itself as a core component of healthcare delivery in NSW, new market reports released today have revealed.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.